Pharmacogenomics and reducing the frequency of adverse drug events.

‘Application of pharmacogenetic and pharmacogenomic information should allow the potential for ADEs to be premanaged in the out-patient setting.’ Drug toxicity and adverse drug events Pharmacogenomics, as applied to medical practice, offers the promise of reduction in adverse drug events (ADEs), enhanced drug efficacy and selection of patients able to respond to specific agents. This editorial will focus on the history and evolving role of pharmacogenetics and pharmacogenomics as it moves from the basic research laboratory into clinical practice to reduce the occurrence of ADEs. In 1994, 2,216,000 patients either reported to the hospital or were in the hospital as a result of ADEs. Of these, 106,000 patients experienced fatal ADEs [1]. In 2000, 2,168,248 toxic events due to all forms of poisons and drugs were reported in the US. Toxin-related events in 2000 affected 8% of the US population. Of these events [2]:

[1]  T R Einarson,et al.  Drug-Related Hospital Admissions , 1993, The Annals of pharmacotherapy.

[2]  J. A. Johnson,et al.  Drug-Related Morbidity and Mortality: A Cost-of-Illness Model , 1995 .

[3]  S. Guharoy,et al.  Suspected Nafcillin-Induced Interstitial Nephritis , 1993, The Annals of pharmacotherapy.

[4]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[5]  U. Hofmann,et al.  MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.

[6]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[7]  Douglas Borys,et al.  2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 2004, The American journal of emergency medicine.

[8]  David L Veenstra,et al.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.

[9]  J. Hochman,et al.  Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. , 2002, Current drug metabolism.

[10]  R. Béliveau,et al.  Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.

[11]  R. Weinshilboum,et al.  Thiopurine methyltransferase polymorphic tandem repeat: Genotype‐phenotype correlation analysis , 2000, Clinical pharmacology and therapeutics.

[12]  R. Traber,et al.  Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. , 2002, Journal of medicinal chemistry.

[13]  P Impicciatore,et al.  Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. , 2001, British journal of clinical pharmacology.

[14]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[15]  M. I. Ngelman-Sundber.  Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy , 2001 .

[16]  F. Bengtsson,et al.  A possible interaction between lithium and rofecoxib. , 2002, British journal of clinical pharmacology.

[17]  D. Sweis,et al.  A Survey on Factors that Could Affect Adverse Drug Reaction Reporting According to Hospital Pharmacists in Great Britain , 2000, Drug safety.

[18]  David S. Miller.  Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants—a case of molecular hijacking , 2002, Journal of biochemical and molecular toxicology.

[19]  T. Adachi,et al.  Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. , 2002, Molecular pharmacology.

[20]  Keizo Sugimachi,et al.  Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene , 2002, Transplantation.

[21]  D. Dormont,et al.  Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. , 2000, AIDS.

[22]  J L Bootman,et al.  Drug-related morbidity and mortality. A cost-of-illness model. , 1995, Archives of internal medicine.

[23]  T. Litovitz,et al.  1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 1998, The American journal of emergency medicine.

[24]  G. Aithal,et al.  CYP2C9 polymorphism and warfarin dose requirements. , 2002, British journal of clinical pharmacology.

[25]  T. Litovitz,et al.  2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. , 2001, The American journal of emergency medicine.

[26]  A. S. Wiener,et al.  Transplantation , 1963 .